Summary. In Malaysia, Tinospora crispa extract is taken orally by Type 2 (non-insulin-dependent) diabetic patients to treat hyperglycaemia. We have evaluated the claimed hypoglycaemic property by adding aqueous extract to the drinking water of normal and alloxan-diabetic rats. After one week, fasting blood glucose levels were significantly (p < 0.01) lower and serum insulin levels were significantly (p < 0.01) higher in treated diabetic animals (10.4___1.0mmol/1 and 12.8+ 1.1 ~tU/ml respectively) compared to untreated diabetic controls (17.4+1.7mmol/1 and 8.0+0.7 ~tU/ml respectively).
Diabetes mellitus has been treated orally with herbal remedies based on folk medicine since ancient times. The discovery of insulin in 1921, followed by oral hypoglycaemic drugs (sulphonylureas in 1955 and biguanides a few years later) has rationalised and simplified the treatment of diabetes [1] . Nevertheless, no medicine capable of eliciting a radical cure for diabetes has yet been discovered. Doubts about the efficacy and safety of present day oral hypoglycaemic agents [2] [3] [4] [5] have prompted a search for safer and more effective drugs in the treatment of diabetes. Traditional herbal remedies which are naturally free from side effects are still in use by diabetic patients, especially in Third World countries [6, 7] , and may, therefore, represent new avenues in the search for alternative hypoglycaemic drugs.
In Malaysia, an aqueous extract derived from boiling the stem of a climbing plant, Tinospora crispa (family: Menispermaceae) [8] is taken orally to treat Type 2 (non-insulin-dependent) diabetes and is claimed to be efficacious [9, 10] . However, to date this claim has not been verified scientifically. In the present study, we have ewduated T. crispa as a potential source of a specific oral hypoglycaemic agent. We have prepared an aqueous extract derived from a traditional preparation of T. crispa stem which demonstrates significant hypoglycaemic and insulinotropic activity in alloxan-diabetic rats. Moreover, the extract stimulates insulin release from rat islets and HIT-T15 B cells in vitro. It is important to extend such observations to humans, and we also show potent insulinotropic activity of the T. crispa extract in isolated human islets of Langerhans.
Materials and methods

Preparation of T. crispa extract
Mature T.erispa stems were obtained from the herb garden of the Universiti Pertanian Malaysia, Serdang, Malaysia. The stems were washed, cut into small pieces, air-dried, ground into powder and boiled and refluxed for 4h. After centrifugation (40 min, 15000 g, 4 ~ C) to separate the aqueous extract from the solid mass, the supernatant was filtered and freeze-dried. The freeze-dried extract was used in all experiments.
The effect of T. crispa on the blood glucose and insulin levels of normal and alloxan-diabetic rats
Male Wistar albino rats (200-300 g) were fasted overnight, then injected intravenously with either an aqueous solution of alloxan monohydrate (Eastman Kodak Co., NY, USA) at a dose of 40 mg/kg body weight [11] , or 154 mmol/1 NaC1. Diabetic rats with fasting blood glucose levels of 14-20 mmol/1 one week after alloxan administration were selected and divided into two groups. Three weeks after alloxan injection, T. erispa extract (4 g/l) was dissolved in the drinking water of the first group (n = 6). Extract administration lasted for two weeks. The diabetic control group (n = 5) received normal food and drink.
Both groups of animals were allowed food and drink ad libitum and blood glucose (Gilford3500 analyser, Gilford Instruments Ltd., Middlesex, UK) and insulin (charcoal radioimmunoassay [20] ) levels were determined at weekly intervals. The same protocol was used for normal rats after 154 mmol/1 NaC1 injection.
Islet isolation and tissue culture
Rat pancreatic islets were prepared by collagenase digestion from fed animals [12] . Isolated islets were collected into tissue culture dishes or 0.45 ~tm Millicell-HA culture inserts (Millipore, Middlesex, UK) using a wire loop under a dissecting microscope. The islets were cultured overnight at 37~ in tissue culture medium RPMI 1640 (Gibco Europe, Paisley, UK) supplemented with 10% (volume/volume) fetal calf serum, streptomycin (0.1 mg/ml), penicillin (0.1 mg/ml) and glucose (11 mmol/1). Human islets were isolated from the pancreata of renal transplant donors (with full ethical committee permission) by collagenase digestion [13] and cultured overnight in RPMI 1640. They were then picked into tissue culture inserts (100 islets/insert) and cultured for a further 24-h period prior to perifusion.
Culture of HIT-T15 cells
HIT-T15 cells were routinely cultured in RPMI 1640 as we have described [14] . The cells were passaged 2-4 days before each experiment and plated in 24-well Nunclon multiwell plates (Gibco Europe, Paisley, UK) or tissue culture inserts at a density of 5 x 105 cells/well (or insert).
Insulin secretion: static incubation
Batches of 5 rat islets were picked into tubes containing 0.6 ml of a modified Krebs-bicarbonate medium with 20 mmol/1 Hepes pH 7.4 and 2 mg/ml albumin [14] , and additions as listed in the results section. After 2 h incubation at 37 ~ C samples were centrifuged briefly to sediment the islets. The supernatant was diluted in phosphate buffer (40 retool/l) containing albumin (1 g/l) and merthiolate (6 mmol/1), and stored at -20~ For HIT-T15 cells, the culture medium was aspirated from the multiwells and replaced with modified Krebs-bicarbonate medium containing 5 mg/ml albumin. After 1 h, this preincubation medium was replaced with buffer containing additions as listed in the results section. After incubation for I h, an aliquot was removed, centrifuged briefly to sediment any detached cells, diluted in phosphate buffer and stored at -20~ Insulin release was measured by charcoal radioimmunoassay [15] .
2 mmol/1 glucose for islets and no glucose for HIT cells. Samples were collected for insulin assay every 2 min, starting at 50 min. Between 60 and 90 min, the perifusion medium was changed for one supplemented as described in the results section. From 90-110 rain, islets or HIT-T15 cells were again perifused with basal medium. The flow rate was 1 ml/min and the system has a dead-space equivalent to 4-6 min.
Glucose utilisation
Rates of glucose utilisation were measured as the formation of 3H20 from [5-3H1 glucose [16] . After culture, the medium was removed and replaced by Hepes-buffered bicarbonate medium. This was replaced after 60 min with medium containing 1 lxCi [5-3H1 glucose (2 or 20 mmol/1) and additions as listed in the results section. After 1 h in an atmosphere of humidified air at 37 ~ C, 100 Ixl aliquots were acidified by the addition of 20 ~tl N HC1 and placed in small tubes inside stoppered scintillation vials containing 0.5 ml H20. After equilibration overnight at 37~ the 3I-I20 recovered in scintillation vials was measured by liquid scintillation spectrometry.
Statistical analysis
For the in vivo studies, the blood glucose and insulin levels are expressed as mean+ SEM. The significance of the effects of T.erispa extract was evaluated by Student's t-test.
We have previously shown that the amount of insulin secreted by HIT-T15 cells varies considerably between passages [14] . Therefore, the following protocol was followed so that data from several experiments could be combined and compared. Each experiment always included 8 control wells containing cells incubated in the absence (4 wells) and in the presence of 10 retool/1 glucose (4 wells). Release rates for test conditions were then expressed as a percentage of the mean value of the appropriate control rates in the same experiment and are given throughout as mean + SEM. Each test condition was examined in five experiments, with 4 replicates per experiment. The mean absolute control rates of insulin secretion are given for each separate series of experiments. The significance of the effects of T. erispa on HIT-T15 insulin release were assessed using the Student's t-test.
A similar protocol was followed for the experiments with isolated rat islets. For the perifusion studies, data from rat islets are presented as mean absolute levels of insulin from three experiments. Data from HIT-T15 cells are, however, presented as a representative of four similar experiments due to the variability in the amount of insulin released by the cells from different passage numbers. Similarly, we have found that individual preparations of human islets are more heterogeneous in terms of islet size, insulin content and absolute levels of insulin released in perifusion. Therefore, insulin secretory data for human islets exposed to either high glucose or T.erispa extract are expressed relative to the basal release of islets from the same individual preparation, and are representative of three separate preparations.
Results
The effect of T. crispa extract on the blood glucose and insulin levels and weight gains of normal and alloxan-diabetic rats Insulin secretion: perifusion
Tissue culture inserts containing islets or HIT cells were transferred to perifusion chambers and perifused continuously for 1 h at 37~ in basal medium consisting of modified Krebs-bicarbonate buffer with Diabetic rats with fasting hyperglycaemia (blood glucose levels of between 74.0-20.0 mmol/1 one week after alloxan injection, were selected for these studies. Figure 1 shows that imrnediately prior to extract administration, there was no significant difference between the blood glucose and insulin levels of the two diabetic groups of animals. However, after only one week, the blood glucose levels of diabetic rats treated with T. crispa extract were significantly lower than controls , and the insulin levels were significantly higher (12.8 _+ 1.1 ~tU/ml vs 8.0 + 0.7 ~tU/ml, p < 0.01). Moreover, this hypoglycaemic and insulinotropic effect was maintained throughout the 2-week treatment. In contrast, the plasma glucose and insulin levels of the untreated diabetic rats remained unchanged throughout the experimental period. In contrast to diabetic animals, there was no significant change in blood glucose and insulin levels in normal rats after T. crispa treatment. Figure 1 also shows that, in contrast to normal rats, the diabetic animals did not gain weight. In fact, there was a slight but significant weight loss three weeks after alloxan administration (from 234.2+4.1 to 216.8 ___ 3.6 g, p < 0.05, n = 6). Thereafter, T. crispa treated animals showed signs of recovery in body weight gains, reaching statistical significance two weeks after treatment (227.5 + 3.6, n = 6) compared to diabetic controls (214.2 _+ 2.1, n = 5, p < 0.05).
The effect of T. crispa extract on insulin release by rat islets
Figure2 shows that T.crispa extract in the range 0.01-1.00 mg/ml induced a dosage dependent initiation of basal (2 mmol/l glucose) insulin release with a maximum 5-fold stimulation. Moreover, over the same range of concentrations, T. crispa potentiated glucose stimulated insulin release 1.5-fold.
The insulinotropic effect of T. crispa was also evident in the perifusion studies (Fig. 3) . Incubation of islets with 10mmol/1 glucose induced stimulation of basal insulin release, the rate of which fell rapidly when the high glucose medium was replaced by 2 mmol/1 glucose. In addition, on restimulation with 10 mmol/1 glucose, there was a further stimulation of insulin release. The addition of T. crispa extract (0.10 mg/ml) to high glucose medium resulted in an essentially similar pattern of insulin release, but was characterised by a more marked augmentation of secretion during periods of stimulation. Figure 4 shows that, as described above for rat islets, T.crispa induced both a dosage dependent initiation
The effect of T. crispa extract on insulin release by HIT-T15 cells
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10 '- and potentiation of glucose-stimulated insulin release in HIT-T15 cells. In the absence of glucose, T. crispa extract (0.01-4.00 mg/ml) stimulated basal HIT-T15 insulin release in a dosage dependent manner, with a 7-fold elevation of basal levels. Over the same concentration range, glucose-stimulated HIT-T15 insulin release was potentiated up to 1.5-fold. When the extracellular glucose concentration was raised from 2 to 20 mmol/1, the rate of HIT-T15 glucose utilisation increased significantly (p < 0.001) from 34.0+1.8 (n=6) to 66.3+4.4 (n=6) nmol glucose/well. However, at both 2 and 20 mmol/1 glucose, T. crispa extract (1 mg/ml) had no significant effect on the rate of glucose utilisation.
In addition, Figure 5 shows that the dosage depend- ent insulinotropic effect of T. crispa was also evident in perifusion studies, and was characterised by the potentiation of both phases of the HIT-T15 insulin secretory response.
The effect of T. crispa extract on insulin release by human islets
The effect of T. crispa on the insulin secretory responsiveness of isolated human islets is shown in Figures 6  and 7 . High glucose (20 mmol/1) alone provoked the stimulation of basal insulin release. The addition of 1.00 mg/ml T. crispa extract to basal medium induced a similar stimulation of insulin secretion to high glucose alone. Moreover, Figure 7 shows that in the human, as in the rodent, T. crispa also potentiated glucose-stimulated insulin release. dition of 1 mg/ml T. crispa except for phosphate content which was higher (p < 0.05, n = 3) in the medium containing the extract.
Glucose, total protein and ionic composition of I mg/ml T. crispa extract
Discussion
It has been estimated that over 25% of the prescription drugs in the USA contain active ingredients of higher plant origin [17] . However, although numerous plant extracts have been claimed to possess hypoglycaemic activity [18] , there have been very few studies of the effects of herbal extracts on insulin secretion and no specific hypoglycaemic agent has yet been identified [6] .
In the present study we have investigated the climber Tinospora crispa, an aqueous extract of which has been traditionally used as an oral hypoglycaemic by diabetic patients in Malaysia. First, an aqueous extract of the stem was prepared using a method which essentially followed the traditional preparation and then the putative hypoglycaemic activity was investigated in normal and alloxan-diabetic rats. Since alloxan may cause partial or even total necrosis of islet B cells [19] , a submaximal dose was chosen (40 mg/kg body weight) to ensure that the animals retained sufficient viable B cells to maintain a moderately hyperglycaemic state (as in Type 2 diabetes). The administration of T. crispa extract to the drinking water of diabetic animals induced a significant hypoglycaemic effect after only one week of treatment. This was associated with a significant increase in the serum insulin levels. Moreover, these effects were maintained throughout the 2-week treatment.
Two weeks after T. crispa treatment, the mean body weight of diabetic animals was significantly higher than that of diabetic controls. Therefore,, the possibility that weight loss could ameliorate Type 2 diabetes can be ruled out. In contrast to diabetic animals, normal rats did not show any significant response to T.crispa treatment.
This may be due to the difference in water consumption (thus amount of extract) between normal and diabetic animals. Lazarow and Palay (1946) reported that diabetic rats drank approximately eight times more water than normal rats. Hence, the actual blood concentration of the extract might not have been high enough to stimulate insulin secretion and affect plasma glucose levels in normal animals. Next, we examined in more detail the potential insulinotropic activity of T.crispa using three in vitro models. T. crispa extract was shown to evoke a dosagedependent stimulation of basal insulin release and also to potentiate glucose-stimulated secretion in rodent models (rat islets, HIT-T15 cells). Moreover, the potent insulinotropic activity of T. crispa "was also evident in isolated human islets. We can also present evidence which demonstrates that the insulin release induced by T. erispa is physiological and does not simply reflect effiux due to toxicity.
First, in all of the perifusion studies insulin secretory rates rapidly fell to basal levels on removal of the T. crispa stimulus. In addition, in rat islets, a second challenge with T.crispa induced an additional, stimulated secretory response. Moreover, the rate of HIT-T15 glucose utilisation was not affected by incubation with T.erispa, suggesting that the cells were viable throughout the experiment. This latter observation also
shows that the insulinotropic activity of T. crispa is not mediated by increased flux through glucose metabolism.
The crude aqueous extract used in these studies is most probably a complex mixture that may contain established insulin secretagogues. Nevertheless, we have been able to show that there were no significant amounts of either glucose or calcium or potassium ions (which in themselves may have been partially responsible for the insulinotropic characteristics) present in the extract at the concentrations used.
In conclusion, these are the first studies to provide biochemical evidence which substantiates the traditional claims for an oral hypoglycaemic effect of Tinospora crispa extract, and which also show that the hypoglycaemic effect is associated with a potent in vitro insulinotropic activity in the human and rat islets and HIT-T15 B cells. Further characterisation of the crude extract may Iead to the isolation of a unique oral hypoglycaemic agent for the treatment of Type 2 diabetes.
